ATR activation has recently been demonstrated as a prognostic biomarker in recurrent ovarian cancer, a highly hypoxic cancer with ATR inhibition shown to be a promising therapeutic approach.[37] PARP inhibitors are an approved treatment for TNBC patients.[71] However, hypoxia in TNBCs has been shown to reduce the efficacy of PARP inhibition, with selective eradication of hypoxic breast cancer cells shown to substantially improving PARPi efficacy.[72] Thus, this provides an opportunity for the combination of PARP inhibition and ICT10336 in TNBCs treatment. This evidence concerns the gene ATR and ovarian carcinoma.